For instance, given the senescence ablation effect of CD11b+Gr-1+ myeloid cells on the PTEN-loss-induced senescent prostate cancer cells, an anti-CXC chemokine receptor 2 (CXCR2) antagonist targeting these myeloid cells can sensitize tumor cells to docetaxel-induced senescence, which ultimately leads to a better treatment outcome of prostate cancer in a mouse model [120]. Here, CXCR2 is linked to prostate carcinoma.